Abbott Diabetes Care has issued a serious warning regarding faulty glucose readings from some of its glucose monitoring devices, specifically the FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors. This issue has been linked to the unfortunate incidents of seven deaths and hundreds of severe injuries. The company confirmed that approximately 3 million of these sensors were affected due to a defect identified through internal testing on a single production line. Of this total, about 1.5 million devices are estimated to have either expired or been utilized.
In an official press release, Abbott explained that the internal testing revealed that certain sensors might deliver incorrect low glucose readings. Customers who suspect that their devices may be impacted are advised to cease usage immediately and dispose of them properly. Abbott emphasized the potential dangers of undetected low glucose readings, which could lead individuals with diabetes to make erroneous treatment decisions, such as consuming excessive carbohydrates or improperly managing their insulin doses. Such mismanagement poses significant health risks, including serious complications and even fatalities.
Although the company continues to manufacture sensors without anticipating major supply disruptions, it has acknowledged the gravity of the situation. Among the seven reported deaths tied to the faulty devices, all occurred outside the United States. Furthermore, of the 736 severe injuries linked to the sensors, 57 were reported within the U.S.
Diabetes profoundly influences the body’s insulin production and response, making accurate glucose monitoring essential for individuals managing the condition. Correct glucose readings are crucial for effective decision-making regarding food intake and medication dosage.
Abbott has provided a resource for affected customers to check the status of their devices at FreeStyleCheck.com. The company is committed to replacing any faulty sensors at no cost to the consumers. For further details regarding the recall and the ongoing situation, the Food and Drug Administration offers additional resources and information.
